Elevance Health, Inc. (ELV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects concerns about Medicaid margin decline, ACA market contraction, and lack of clarity on certain financial metrics. Despite some positive developments in specialty pharmacy and Medicare strategy, the overall tone is cautious with significant risks in Medicaid and ACA markets. The revised EPS guidance and potential Medicaid margin trough in 2026 suggest challenges ahead. The market is likely to react negatively, especially without clear guidance on key metrics, leading to a predicted stock price movement in the -2% to -8% range.
Key Financial Performance
GAAP diluted earnings per share (EPS) $5.32 for the third quarter, reflecting enhanced medical cost management and expense discipline.
Adjusted diluted earnings per share (EPS) $6.03 for the third quarter, benefiting from planned tax actions and stronger net investment income.
Total operating revenue $50.1 billion for the quarter, up 12% year-over-year, driven by higher premium yields, acquisitions, and Medicare Advantage membership growth, partially offset by Medicaid reverifications.
Medical membership 45.4 million members at the end of the quarter, with Medicaid membership concentrated among lower acuity members due to stringent eligibility reviews.
Consolidated benefit expense ratio 91.3%, aligned with expectations, with Medicaid performance pressured by elevated acuity and utilization not fully offset by rate updates.
Medicaid operating margin Expected to be modestly negative for 2025, with a projected decline of at least 125 basis points in 2026 due to rate misalignment and elevated trends.
Carelon Rx revenue Grew 20% year-over-year, driven by momentum with large clients.
Carelon Services revenue Grew by more than 50%, supported by organic growth and integration of CareBridge.
Net investment income $625 million for the quarter, including $150 million from discrete valuation adjustments in the alternatives investment portfolio.
Operating cash flow $1.1 billion for the quarter, impacted by a cash settlement payment related to the Blue Cross Blue Shield litigation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled virtual assistant: By year-end, more than 10 million members will have access to this tool, enhancing access, efficiency, and engagement.
HealthOS platform: Providers benefit from aligned data sharing, faster approvals, and reduced administrative burden.
Carelon external revenue: Grew double digits year-over-year, driven by pharmacy, behavioral, and specialty services.
Carelon Rx: Strong selling season for 2026 with several national account wins and high retention.
Medicaid operating margin: Expected to decline by at least 125 basis points in 2026 due to rate misalignment and elevated utilization trends.
Carelon Rx revenue: Grew 20% year-over-year, driven by momentum with large clients.
Carelon Services revenue: Grew by more than 50%, supported by organic growth and integration of CareBridge.
Medicare Advantage strategy: Exiting plans not aligned with long-term strategy and focusing on retention and value.
Capital deployment: Focus on integrating recent acquisitions and prioritizing shareholder returns through share repurchases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Rising medical and pharmacy costs: The healthcare industry is facing challenges due to increasing medical and pharmacy costs, which could impact the company's ability to manage expenses and maintain profitability.
Regulatory changes: Regulatory changes are expected to impact coverage for millions of Americans, creating uncertainties and potential operational challenges for the company.
Medicaid reverifications and state program changes: Membership reverifications and state program changes have increased acuity and utilization trends, leading to a projected 125 basis point decline in Medicaid margins for 2026.
Medicare Advantage profitability: The company is exiting certain plans not aligned with its long-term strategy, which could impact membership and profitability in the short term.
Expiration of enhanced subsidies in ACA market: The anticipated expiration of enhanced subsidies could significantly impact membership in 2026, creating financial and operational challenges.
Enrollment dynamics in Health Benefits: Enrollment dynamics are expected to create a directional headwind for Carelon in the next year, potentially affecting revenue and growth.
Elevated utilization trends in Medicaid: Elevated utilization trends in Medicaid are not fully offset by rate updates, leading to a modestly negative operating margin for 2025 and further declines expected in 2026.
Higher costs in ACA market: Cost trends in the ACA market remain significantly above historical levels, impacting operating margins and financial performance.
Investments in technology and operational efficiency: Targeted investments in technology and operational efficiency are expected to impact Carelon Rx margins, though they are necessary for long-term growth.
State-specific program changes in Medicaid: Funding and eligibility changes in certain states are creating uncertainties and challenges in Medicaid operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Adjusted EPS: Reaffirmed at approximately $30, with $27 as the baseline excluding $3 of discrete nonrecurring items.
2026 Medicaid Margins: Expected to decline by at least 125 basis points year-over-year due to elevated acuity and utilization trends, and rate misalignment.
Medicare Advantage Profitability: Disciplined actions taken to improve profitability in 2026, focusing on retention and value-driven products while exiting non-strategic plans.
Medicare Advantage Star Ratings: For 2027 payment year, 55% of members expected to be in 4-star or higher contracts, up from 40% in 2026.
ACA Market Membership: Anticipated expiration of enhanced subsidies could significantly impact membership in 2026. If subsidies are extended, the company will work with states to ensure continued access.
Carelon Growth: Continued expansion in pharmacy, behavioral health, specialty care management, and home-based services. Carelon Rx achieved strong national account wins for 2026.
Capital Deployment: Focus on integrating recent acquisitions, disciplined capital allocation, and prioritizing share repurchases while balancing growth investments.
2027 Outlook: Expected return to a more balanced earnings growth profile after challenging Medicaid dynamics and membership changes in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Capital deployment: Capital deployment remains an important lever in our long-term earnings growth algorithm. Following several years of strategic acquisitions to expand Carelon's capabilities, our focus is now on integrating those assets. We remain committed to disciplined capital allocation, balancing investment in growth with consistent shareholder returns.
Share repurchases: We will prioritize returning capital to shareholders through share repurchases, while remaining disciplined stewards of capital.
Share repurchase activity: In the quarter, we repurchased $875 million of shares, reflecting our disciplined approach to capital deployment and commitment to returning value to shareholders even as we continue integrating recent acquisitions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key factors affecting Medicaid margins in 2026?
A:Medicaid margins in 2026 are expected to decline by at least 125 basis points due to elevated acuity and utilization driven by state reverification processes and program changes. Rates are expected to be modestly above historical levels but will still trail trends. The company views 2026 as the trough year for Medicaid margins, with actions being taken to improve margins over time.
Q:What investments is the company planning for 2026, and what are the focus areas?
A:The company plans to make discrete investments worth several hundred million dollars, approximately $1 of EPS, in 2026. The focus areas include technology adoption (e.g., AI in clinical workflows), Carelon investments (e.g., scaling new client onboarding and building pharmacy capabilities), and operational and quality initiatives (e.g., improving Star ratings and member engagement). These investments aim to align with long-term growth objectives and enhance operational leverage.
Q:What is the company's outlook on the ACA exchanges and membership impact if enhanced subsidies are not extended?
A:If enhanced subsidies are not extended, the company expects a material contraction in the ACA marketplace, with lower enrollment and a higher morbidity risk pool in 2026. The company has taken a balanced approach in its filings to reflect higher acuity and is prepared for a range of policy outcomes, including renewal or modification of subsidies.
Q:What is the status of Medicare margins and the company's strategy for improvement?
A:Medicare margins are expected to show stability with potential slight improvement in 2025, supported by strong retention, disciplined cost management, and product positioning. The company has taken actions such as plan exits and benefit reductions to improve margins and aims to return to the target range of 3%-5% over time.
Q:What is the company's approach to managing Medicaid contracts with significant negative margins?
A:The company evaluates Medicaid contracts based on rate adequacy, program design, regulatory environment, and other factors. If a state cannot deliver financial expectations, the company may consider exiting the contract, aligning such decisions with normal contract renewal cycles to minimize disruption.
Q:What progress has been made in Carelon Rx and specialty pharmacy?
A:The company has made significant progress in its specialty pharmacy strategy, including the migration of scripts to the BioPlus platform and the integration of Kroger Specialty Pharmacy. These efforts are part of a broader strategy to diversify and grow Carelon Rx, including garnering scripts outside of Elevance Health.
Q:What are the company's expectations for Medicaid membership and revenue in 2026?
A:Medicaid membership is expected to be modestly lower in 2026 due to continued normalization following redeterminations and state program changes. Revenue growth will depend on factors like rate updates and program changes, but the company is taking a prudent approach to planning.
Q:How is the company addressing elevated coding trends from providers?
A:The company is working with providers to ensure accuracy, compliance, and sustainability in how member conditions are documented. Steps include improving oversight of data capture, clinical documentation, and vendor management.
Q:What is the company's strategy for Medicare Advantage, particularly for D-SNP and PPO products?
A:The company is focusing on HMO and D-SNP products, which align with its Medicaid footprint and value-based care strategy. PPO products have not been a strong focus and are being scaled back. The company aims to improve profitability and achieve long-term target margins in Medicare Advantage.
Q:What are the company's expectations for commercial cost trends?
A:Commercial cost trends are mostly in line with expectations, with some pressure in areas like outpatient utilization, behavioral health, and higher-cost surgeries. The ACA market has shown some favorability despite elevated utilization and risk pool acuity.
Q:Review of Unclear Management Responses
A:Management avoided providing specific point estimates for Medicaid composite rate updates and medical cost trends. They also did not quantify the impact of potential benefit design changes in Medicaid or provide a clear bottom limit for Medicaid margin expectations in 2026. Additionally, they did not offer detailed guidance on the impact of the OB3 provisions on Medicaid margins or the exact membership impact of ACA subsidy changes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP result
AI assistant
AI support
Advantage action
Americans Elevance
Benefits headwind
CEO Kaye
Capital deployment
Carelon relationship
Clients value
Commercial pharmacy
Health Conference
Health care
Health cost
Health visibility
Kaye CFO
Medicaid reverification
Medicare AEP
Net Promoter
Promoter Scores
Relations Boudreaux
affordability
approach pricing
capital
client retention
cost curve
discipline focus
industry
input
lever
model
planning
platform
program change
return
star contract
state program
subsidy
value care
ELV Transcript
Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-11
Elevance Health, Inc. (ELV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Elevance Health, Inc. (ELV) Q4 2025 Earnings Call Transcript
Unknown1-28
The earnings call presents several concerns: declining Medicaid margins, membership losses, and unclear management responses. Despite some positive aspects like Carelon growth and strategic repositioning, these are overshadowed by negative trends and uncertainties, particularly around Medicare and Medicaid. The Q&A revealed further risks and lack of clarity, which likely weigh on investor sentiment. Given these factors, along with the absence of strong positive catalysts, a negative stock price reaction is anticipated.
Elevance Health, Inc. (ELV) Q3 2025 Earnings Call Transcript
Unknown10-21
The earnings call reflects concerns about Medicaid margin decline, ACA market contraction, and lack of clarity on certain financial metrics. Despite some positive developments in specialty pharmacy and Medicare strategy, the overall tone is cautious with significant risks in Medicaid and ACA markets. The revised EPS guidance and potential Medicaid margin trough in 2026 suggest challenges ahead. The market is likely to react negatively, especially without clear guidance on key metrics, leading to a predicted stock price movement in the -2% to -8% range.
ELV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
